
Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2024-2030
Description
Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Global Forecast 2024-2030
The Ankylosing Spondylitis Market size was estimated at USD 5.18 billion in 2023 and expected to reach USD 5.60 billion in 2024, at a CAGR 8.31% to reach USD 9.06 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Ankylosing Spondylitis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ankylosing Spondylitis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Ankylosing Spondylitis Market, highlighting leading vendors and their innovative profiles. These include Biothera Pharmaceuticals, Inc. by HiberCell, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celltrion Healthcare Co.,Ltd., Eisai Co., Ltd, Eli Lilly and Company, Hetero Drugs Limited, Novartis AG, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi-Aventis Groupe S.A., Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech PLC, and Xian Janssen Pharmaceutical Ltd.
Market Segmentation & Coverage
This research report categorizes the Ankylosing Spondylitis Market to forecast the revenues and analyze trends in each of the following sub-markets:
Drug
Cimzia
Biologics
Cyclooxygenase Inhibitors
Oral
Liquid
Clinics
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Ankylosing Spondylitis Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ankylosing Spondylitis Market?
- What are the technology trends and regulatory frameworks in the Ankylosing Spondylitis Market?
- What is the market share of the leading vendors in the Ankylosing Spondylitis Market?
- Which modes and strategic moves are suitable for entering the Ankylosing Spondylitis Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
193 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Ankylosing Spondylitis Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing incidences of ankylosing spondylitis
- 5.1.1.2. Growing awareness about diagnostics and treatments for the disease
- 5.1.1.3. Rising number of orthopedic hospitals and diagnostic centers
- 5.1.2. Restraints
- 5.1.2.1. High cost of treatment and dearth of skilled surgeons and physiotherapists
- 5.1.3. Opportunities
- 5.1.3.1. Acceleration in research and development expenditure for the treatment of the spondylitis
- 5.1.3.2. The emergence of biologics for treating ankylosing spondylitis
- 5.1.4. Challenges
- 5.1.4.1. Concerns related to patent expiration of already approved drugs
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Ankylosing Spondylitis Market, by Drug
- 6.1. Introduction
- 6.2. Cimzia
- 6.3. Cosentyx
- 6.4. Enbrel
- 6.5. Humira
- 6.6. Remicade
- 6.7. Simponi
- 7. Ankylosing Spondylitis Market, by Type of Molecule
- 7.1. Introduction
- 7.2. Biologics
- 7.3. Small Molecules
- 8. Ankylosing Spondylitis Market, by Mechanism Of Action
- 8.1. Introduction
- 8.2. Cyclooxygenase Inhibitors
- 8.3. Tumor Necrosis Factor Inhibitors
- 9. Ankylosing Spondylitis Market, by Route Of Administration
- 9.1. Introduction
- 9.2. Oral
- 9.3. Parenteral
- 10. Ankylosing Spondylitis Market, by Dosage Forms
- 10.1. Introduction
- 10.2. Liquid
- 10.3. Solid
- 11. Ankylosing Spondylitis Market, by End User
- 11.1. Introduction
- 11.2. Clinics
- 11.3. Hospitals
- 12. Americas Ankylosing Spondylitis Market
- 12.1. Introduction
- 12.2. Argentina
- 12.3. Brazil
- 12.4. Canada
- 12.5. Mexico
- 12.6. United States
- 13. Asia-Pacific Ankylosing Spondylitis Market
- 13.1. Introduction
- 13.2. Australia
- 13.3. China
- 13.4. India
- 13.5. Indonesia
- 13.6. Japan
- 13.7. Malaysia
- 13.8. Philippines
- 13.9. Singapore
- 13.10. South Korea
- 13.11. Taiwan
- 13.12. Thailand
- 13.13. Vietnam
- 14. Europe, Middle East & Africa Ankylosing Spondylitis Market
- 14.1. Introduction
- 14.2. Denmark
- 14.3. Egypt
- 14.4. Finland
- 14.5. France
- 14.6. Germany
- 14.7. Israel
- 14.8. Italy
- 14.9. Netherlands
- 14.10. Nigeria
- 14.11. Norway
- 14.12. Poland
- 14.13. Qatar
- 14.14. Russia
- 14.15. Saudi Arabia
- 14.16. South Africa
- 14.17. Spain
- 14.18. Sweden
- 14.19. Switzerland
- 14.20. Turkey
- 14.21. United Arab Emirates
- 14.22. United Kingdom
- 15. Competitive Landscape
- 15.1. FPNV Positioning Matrix
- 15.2. Market Share Analysis, By Key Player
- 15.3. Competitive Scenario Analysis, By Key Player
- 16. Competitive Portfolio
- 16.1. Key Company Profiles
- 16.1.1. Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
- 16.1.2. Boehringer Ingelheim International GmbH
- 16.1.3. Bristol-Myers Squibb
- 16.1.4. Celltrion Healthcare Co.,Ltd.
- 16.1.5. Eisai Co., Ltd
- 16.1.6. Eli Lilly and Company
- 16.1.7. Hetero Drugs Limited
- 16.1.8. Novartis AG
- 16.1.9. Reliance Life Sciences
- 16.1.10. Samsung Bioepis Co., Ltd.
- 16.1.11. Sandoz International GmbH
- 16.1.12. Sanofi-Aventis Groupe S.A.
- 16.1.13. Shanghai Pharmaceuticals Holding Co., Ltd.
- 16.1.14. Trinity Biotech PLC
- 16.1.15. Xian Janssen Pharmaceutical Ltd
- 16.2. Key Product Portfolio
- 17. Appendix
- 17.1. Discussion Guide
- 17.2. License & Pricing
- FIGURE 1. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
- FIGURE 2. ANKYLOSING SPONDYLITIS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANKYLOSING SPONDYLITIS MARKET DYNAMICS
- FIGURE 7. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
- FIGURE 8. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2030 (%)
- FIGURE 10. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
- FIGURE 12. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 14. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
- FIGURE 16. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
- FIGURE 18. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 22. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 24. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 27. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 28. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.